Introduction {#s1}
============

Dystroglycan (DG) is a basement membrane receptor composed of an extracellular α subunit and a transmembrane β subunit, and is involved in maintenance of the integrity of the skeletal muscle membrane, as well as the structure and the function of the central nervous system ([@CWS152C4]). α-dystroglycan (α-DG) is highly decorated with *O*-glycans, and modification with a specific, unusual *O*-mannosyl glycan is essential for its binding to laminin-G domain-containing extracellular matrix (ECM) ligands, such as laminin, perlecan and agrin in muscle ([@CWS152C16]; [@CWS152C11]; [@CWS152C33]), neurexin in the brain ([@CWS152C32]) and pikachurin in the retina ([@CWS152C27]). Notably, the same modification is required for the binding of α-DG to Old World arenaviruses ([@CWS152C7]).

Several lines of evidence have demonstrated that defects in *O*-mannosyl glycan synthesis cause congenital muscular dystrophies with brain abnormalities that are characterized by perturbed α-DG glycosylation and a reduction in the ability of α-DG to bind ligands (referred to as the dystroglycanopathies) ([@CWS152C12]). First, mutations in genes encoding known and putative glycosyltransferases involved in *O*-mannosyl glycan synthesis have been identified in dystroglycanopathy patients ([@CWS152C4]). The affected proteins include: The like-acetylglucosaminyltransferase (LARGE), protein *O*-mannosyltransferase 1 (POMT1), POMT2, protein *O*-mannosyl β-1,2-*N*-acetylglucosaminyltransferase 1 (POMGnT1), fukutin and fukutin-related protein (FKRP). In addition, it has been recently found that mutations in ISPD (isoprenoid synthase domain containing) cause Walker--Warburg syndrome, a type of dystroglycanopathy, and defective *O*-mannosylation of α-DG ([@CWS152C25]; [@CWS152C34]). Secondly, the LARGE mutation present in the *Large^myd^* mouse model of muscular dystrophy results in defective α-DG glycosylation ([@CWS152C13]). Thirdly, laminin-binding of α-DG requires phosphorylation of *O*-linked mannose, and LARGE, fukutin and FKRP have all been implicated in the modification pathway that assembles the laminin-binding moiety on this phosphorylated *O*-mannosyl glycan ([@CWS152C36]).

We recently reported that LARGE is a bifunctional glycosyltransferase that alternately transfers xylose (Xyl) and glucuronic acid (GlcA) to α-DG, to form a polysaccharide that confers the ability to bind ligands ([@CWS152C17]). Notably, overexpression of LARGE enhances the functional modification of α-DG in cultured cells ([@CWS152C5]; [@CWS152C18]). Overexpression of LARGE2, a paralog of LARGE, has been shown to enhance the modification of α-DG to a similar degree ([@CWS152C6]; [@CWS152C10]; [@CWS152C14]). LARGE2 has been cloned from human kidney, mouse kidney and mouse testis RNA, and the two paralogs have different tissue expression profiles: LARGE is widely expressed, with levels highest in the brain, heart and skeletal muscle; and LARGE2 is highly expressed in the kidney and the placenta, but not in the brain ([@CWS152C10]; [@CWS152C14]). In spite of this characterization of LARGE2 expression, neither its contribution to the functional modification of α-DG in vivo nor its enzymatic activities have been assessed.

Here, we demonstrate that LARGE2 has xylosyltransferase (Xyl-T) and glucuronyltransferase (GlcA-T) activities as well as polymerizing activity, and in these respects it resembles LARGE. However, we also show that the pH optima for the Xyl-T and GlcA-T activities are distinct and that they differ significantly from those of LARGE. These results suggest that both LARGE paralogs are involved in the functional modification of α-DG, but that they may be fine-tuned to function optimally in different physiological contexts.

Results {#s2}
=======

Cellular xylosylation is essential for the functional modification of α-DG as it has been shown that uridine 5′-diphosphate (UDP)-xylose synthase 1 (UXS1)-deficient Chinese hamster ovary (CHO) cells (line pgsI-208) that lack UDP-Xyl ([@CWS152C3]) have a defect in the modification of α-DG, and overexpression of LARGE in the cells did not rescue the defect ([@CWS152C17]). We examined whether overexpression of LARGE2 could rescue the defect or not, by immunoblotting of glycoproteins and flow cytometry for cell surface staining with IIH6 (an antibody that recognizes the laminin-binding form of α-DG). When LARGE2 was overexpressed in the wild-type (WT) CHO cells, a robust increase in the functional modification was observed (Figure [1](#CWS152F1){ref-type="fig"}A and [Supplementary data, Figure S1](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)), as has been reported previously ([@CWS152C6]; [@CWS152C10]; [@CWS152C14]). In contrast, overexpression of LARGE2 did not overcome the defect in pgsI-208 cells as is also the case with LARGE overexpression (Figure [1](#CWS152F1){ref-type="fig"}A and B), which is consistent with our previous observation. Thus, cellular xylosylation is required for the LARGE2-dependent functional modification of α-DG, as shown for LARGE. Fig. 1.Overexpression of the LARGE paralog does not overcome the glycosylation defect in UXS1-deficient (pgsI-208) CHO cells. (**A**) Immunoblotting of WGA-enriched glycoproteins for functionally modified α-DG (IIH6) and β-DG, or of cell lysates for LARGE and LARGE2, from WT or pgsI-208 cells with or without overexpression of either LARGE or LARGE2. *M*r, relative molecular mass. (**B**) Flow cytometry of the cells for surface staining with IIH6. Dotted line, secondary antibody alone.

LARGE and LARGE2 share two conserved glycosyltransferase-like domains: One that belongs to glycosyltransferase family 8 (GT8) proteins ([@CWS152C8]) and one that is shared with β1,3-*N*-acetylglucosaminyltransferase 1, an enzyme required for poly-*N*-acetyllactosamine synthesis ([@CWS152C26]; [@CWS152C24]). In addition, the DXD motifs required for the LARGE function are conserved in LARGE2 ([@CWS152C6]; [@CWS152C17]). It has been demonstrated that all the three DXD motifs are required for LARGE to be functional ([@CWS152C6]), and single DXD mutants in different domains do not complement one another biochemically ([@CWS152C1]). To investigate the glycosyltransferase activities of LARGE2, we generated a secreted form that lacks the transmembrane domain (LARGE2dTM) and includes both an N-terminal FLAG and C-terminal myc + Hisx6 tags (Figure [2](#CWS152F2){ref-type="fig"}A). Purified LARGE2dTM (Figure [2](#CWS152F2){ref-type="fig"}B) was tested for in vitro enzymatic assay using 4-methylumbelliferyl-β-[d]{.smallcaps}-glucuronide (GlcA-β-MU) or *p*-nitrophenyl-α-[d]{.smallcaps}-xyloside (Xyl-α-pNP) as acceptors, and the products were analyzed by high-performance liquid chromatography (HPLC) using an LC-18 column as described previously ([@CWS152C17]). When GlcA-β-MU was used as the acceptor and UDP-Xyl as the donor, a unique peak was generated by adding LARGE2dTM (Figure [3](#CWS152F3){ref-type="fig"}A). This peak was eluted at the same retention time as the product resulting from catalysis by LARGEdTM ([Supplementary data, Figure S2A](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)). When this product was purified and analyzed by mass spectrometry (MS), the MS/MS fragmentation pattern of a parent ion at a mass/charge ratio (*m*/*z*) of 483.14 \[M--H\]^−^ confirmed that Xyl was attached to GlcA-β-MU (Figure [3](#CWS152F3){ref-type="fig"}B and [Supplementary data, Figure S3A](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)). When Xyl-α-pNP was used as the acceptor and UDP-GlcA as the donor (Figure [3](#CWS152F3){ref-type="fig"}C), a unique peak appeared and the retention time was the same as that of the LARGEdTM product ([Supplementary data, Figure S2B](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)). MS analysis confirmed that GlcA was attached to Xyl-α-pNP (Figure [3](#CWS152F3){ref-type="fig"}D and [Supplementary data, Figure S3B](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)). Fig. 2.Purification of LARGE2dTM. (**A**) Schematic representation of LARGE and the LARGEdTM construct as described previously ([@CWS152C17]), and LARGE2 and the LARGE2dTM construct used in the enzymatic activity assay. The transmembrane (TM) sequence of LARGE2 was replaced with a FLAG (3x) tag sequence, and the C-terminus was modified with myc and Hisx6 tags. CC, coiled-coil domain. (**B**) Expression and purification of test proteins. (Left) Immunoblotting with anti-FLAG antibody. For each stable clone, 50 μL of the culture medium was analyzed. pCMV9, cell clone obtained by transfection of empty vector. (Right) Purification of recombinant LARGE2dTM protein expressed in the culture medium. Proteins were run over the Talon metal affinity resin and eluted, and the fractions were analyzed by Coomassie brilliant blue (CBB) staining. Fig. 3.LARGE2 is a bifunctional glycosyltransferase with Xyl-T and GlcA-T activities. (**A**) HPLC elution profile from the LC-18 column of the products obtained from the reaction of LARGE2dTM with GlcA-β-MU and UDP-Xyl. S, unreacted substrate. P, product. Dashed line, %Buffer B. (**B**) Q/TOF-MS analysis of the product peak detected in (**A**). Star and diamond indicate Xyl and GlcA, respectively. The MS/MS fragmentation pattern ([Supplementary data, Figure S3A](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)) confirmed that the ion with an *m*/*z* of 483.14 \[M--H\]^−^ is GlcA-β-MU with an added Xyl. (**C**) HPLC elution profile from the LC-18 column of the products obtained from the reaction of LARGE2dTM with Xyl-α-pNP and UDP-GlcA. (**D**) Q/TOF-MS analysis as in (**B**), for the product isolated from the reaction analyzed in (**C**). The MS/MS fragmentation pattern ([Supplementary data, Figure S3B](http://glycob.oxfordjournals.org/lookup/suppl/doi:10.1093/glycob/cws152/-/DC1)) confirmed that the ion with an *m*/*z* of 446.17 \[M--H\]^−^ is Xyl-α-pNP with an added GlcA. (**E**) Donor substrate specificity of LARGE2dTM. Representative data from two independent assays, showing relative activity (%) of Xyl-T toward GlcA-β-MU and of GlcA-T toward Xyl-α1,3-GlcA-β-MU. No other sugars were transferred to the acceptors.

We next tested the ability of LARGE2 to modify substrate with other sugars. However, the acceptor substrate pair used for the experiments described above were not ideal because the nonfluorescent Xyl-α-pNP acceptor (a fluorescent α-linked xyloside was not available at the time of the study) used to analyze GlcA-T activity was not as sensitive as the fluorescent acceptor GlcA-β-MU used for Xyl-T activity. Thus, we instead used Xyl-α1,3-GlcA-β-MU, the product of the reaction of LARGEdTM with GlcA-β-MU and UDP-Xyl ([@CWS152C17]), as the acceptor in this analysis. Testing of various donor sugars for LARGE2dTM activity in conjunction with the acceptors GlcA-β-MU and Xyl-α1,3-GlcA-β-MU confirmed that LARGE2 transfers Xyl and GlcA, respectively, but no other sugars (Figure [3](#CWS152F3){ref-type="fig"}E). Thus, LARGE2 is a bifunctional glycosyltransferase that, like LARGE, has both Xyl-T and GlcA-T activities.

We also assessed LARGE2 for the polymerizing activity necessary to generate polysaccharide on the acceptor. To this end, we performed the LARGE2dTM reaction with GlcA-β-MU, using both UDP-Xyl and UDP-GlcA as donors, and then separated the products using an amide column. Multiple product peaks were generated (Figure [4](#CWS152F4){ref-type="fig"}A) as has been observed with LARGEdTM ([@CWS152C17]). We isolated the product peaks (peaks 1--3) and further purified them by running them over an LC-18 column (Figure [4](#CWS152F4){ref-type="fig"}B). MS analysis of the peaks showed *m*/*z* values corresponding to those of the products expected to be modified by Xyl and GlcA (Figure [4](#CWS152F4){ref-type="fig"}C); thus, LARGE2 is also a polymerizing enzyme capable of synthesizing Xyl-GlcA repeats. Fig. 4.LARGE2dTM has polymerizing activity. (**A**) HPLC profile of the reaction products generated when LARGE2dTM was added to GlcA-β-MU in the presence of both donors, UDP-Xyl and UDP-GlcA, on the amide column GlycoSep N. Peaks labeled 1--3 were subjected to further purification in (**B**). S, unreacted substrate. Dashed line, %Buffer B. (**B**) Purification of GlcA-β-MU derivatives on an LC-18 column. Each peak isolated in (**A**) was purified and the main peak was collected (solid bar). (**C**) Q/TOF-MS analysis of the peaks isolated in (**B**). Assigned mass spectra in each peak confirmed that LARGE2dTM added repeating units of Xyl and GlcA onto the acceptor, GlcA-β-MU. dp, degree of polymerization.

We assessed both LARGEdTM and LARGE2dTM for the pH optima of the Xyl-T and GlcA-T activities. Interestingly, in the case of LARGEdTM, Xyl-T activity was optimal at pH 5.0 but GlcA-T activity was efficient across a broad pH range (5.5--pH 8.0; Figure [5](#CWS152F5){ref-type="fig"}A). LARGE2dTM showed a distinctly different pattern, with a relatively broad effective pH range for Xyl-T activity (5.5--pH 9.0) but a sharp optimum with respect to the GlcA-T activity (pH 5.5; Figure [5](#CWS152F5){ref-type="fig"}B). Thus, each LARGE paralog has distinct enzymatic characteristics in spite of catalyzing the same glycosylation reactions. Fig. 5.LARGEdTM and LARGE2dTM have distinct pH optima for the Xyl-T and GlcA-T activities. Data from two independent experiments are shown as relative activity (%). The highest activity in the dataset was arbitrarily set at 100%. The Xyl-T and the GlcA-T assays were carried out using GlcA-β-MU and Xyl-α1,3-GlcA-β-MU as the acceptors, respectively. The buffers used were: Acetate for pH 4.0--5.5 (empty circles), MES for pH 5.5--6.5 (closed circles), MOPS for pH 6.5--8.0 (empty triangles) and Tris--HCl for pH 8.0--9.0 (closed triangles). The details of the conditions are presented in the Materials and methods section.

Discussion {#s3}
==========

The high degree of similarity between LARGE and LARGE2 with respect to sequence and domain structure, as well as the fact that both proteins enhance the functional modification of α-DG, suggested that LARGE2 likely has the same glycosyltransferase activities as LARGE. In this study, we have demonstrated that LARGE2 indeed has Xyl-T and GlcA-T activities and polymerizing activity in vitro, using an enzymatic assay with recombinant LARGE2dTM protein.

The Xyl-T activities of both LARGE and LARGE2 require UDP-Xyl as the donor substrate, consistent with our finding that the UXS1-deficient cell line pgsI-208, which lacks UDP-Xyl, shows defective glycosylation of α-DG. Our current result that overexpression of LARGE2 did not rescue the functional modification in pgsI-208 cells, as previously shown for LARGE, is consistent with this explanation.

Our results reveal that, in contrast to *O*-mannosylation of α-DG, which requires coexpression of the paralogs POMT1 and POMT2 in vitro and in vivo ([@CWS152C20]; [@CWS152C35]), functional glycosylation involves LARGE paralogs that can act independently. This is consistent with the previous observation that the kidneys (in which the *LARGE2* mRNA is highly expressed) of *Large^myd^* mice retain substantial functional glycosylation of α-DG ([@CWS152C14]), which suggests that LARGE2 is enzymatically active in the absence of LARGE in vivo. Our results are consistent with our previous study revealing that the heteropolysaccharide generated by the polymerizing activity of LARGE conferred ligand-binding ability on α-DG ([@CWS152C17]); here, we have demonstrated that LARGE2 has polymerizing activity. This is probably the feature that makes it possible for α-DG to bind ECM ligands as reported in previous studies involving the overexpression of LARGE2 in cultured cells ([@CWS152C6]; [@CWS152C10]; [@CWS152C14]).

Molecular recognition of the α-DG N-terminus by LARGE is an essential step for the production of functional α-DG ([@CWS152C18]). Moreover, a recent study has shown that the LARGE-dependent modification required for laminin- and Old World arenavirus-binding occurs on specific Thr residues located at the extreme N-terminus of the α-DG mucin-like domain ([@CWS152C15]). Since this domain contains a number of potential *O*-glycosylation sites and some other sites have also been shown to be *O*-mannosylated in human and rabbit skeletal muscle α-DG ([@CWS152C22]; [@CWS152C30]), it will be interesting to test whether LARGE2 has the same α-DG glycosylation-site preference as LARGE.

Most notably, we found that the LARGE paralogs have different pH optima for their enzymatic activities. In the case of LARGE2, the Xyl-T reaction was productive across the broad pH range 5.5--9.0, whereas the GlcA-T counterpart was most productive at a pH 5.5, and LARGE had almost the opposite characteristics (pH optimum for the Xyl-T reaction at pH 5.0, and that for GlcA-T across the range of pH 5.5--8.0; Figure [5](#CWS152F5){ref-type="fig"}). Although the physiological significance of the different pH optima is unclear, it suggests that the LARGE paralogs may be fine-tuned to function optimally under different physiological conditions in the intracellular milieu. Different types of cells and tissues may have different sets of the possible cofactors for the functional modification of α-DG, and even in the same tissues there might be possibly differences in relative expression levels and compartmentalization of the LARGE paralogs in the Golgi apparatus. Those differences could affect the formation of a functional complex or the interaction of each LARGE paralog with its cofactors resulting in more efficient modification of α-DG.

With regard to the mechanisms whereby LARGE and LARGE2 may complement one another, it is interesting to consider the biology of the bifunctional glycosyltransferases EXT1 and EXT2, which are associated with the development of hereditary multiple exostoses ([@CWS152C2]; [@CWS152C31]). These enzymes have GlcA-T and *N*-acetylglucosaminyltransferase (GlcNAc-T) activities that are required for the synthesis of heparan sulfate ([@CWS152C19]; [@CWS152C21]), and recombinant forms of EXT1 and EXT2 have both GlcA-T and GlcNAc-T activities in vitro. Notably, their coexpression yields hetero-oligomeric complexes with augmented glycosyltransferase activities ([@CWS152C28]). Although we currently have no evidence to indicate that LARGE and LARGE2 form a heteromeric complex, such a mechanism could potentially account for complementary activity with respect to α-DG, when one or the other glycosyltransferase is inefficient at a certain pH. On the basis of the fact that the overexpression of LARGE can restore functional modification of α-DG in cells from dystroglycanopathy patients who have mutations in other genes, as well as laminin-binding, it has been suggested that LARGE is a potential target in treating dystroglycanopathies ([@CWS152C5]; [@CWS152C12]). Our current results support this notion and further suggest that LARGE2 could be considered for such a role. Therefore, all efforts should be made to better understand the mechanisms behind and requirements for its enzymatic activities.

Materials and methods {#s4}
=====================

Antibodies {#s4a}
----------

Antibodies to glycosylated α-DG (IIH6), β-DG (7D11) and LARGE have been described previously ([@CWS152C9]; [@CWS152C23]; [@CWS152C18]). Antibodies against mouse LARGE2 were generated by injecting a keyhole limpet hemocyanin (KLH)-conjugated synthetic peptide corresponding to the C-terminal sequence of mouse LARGE2 (C-SAALKYLTALQQARSRA) into rabbits (Rbt340). The polyclonal anti-LARGE2 antibodies were affinity-purified using a bovine serum albumin (BSA)-conjugated C-terminal peptide as described ([@CWS152C29]). The above-described monoclonal antibodies, as well as the other antibody that recognizes glycosylated α-DG (VIA4-1) are available from the Developmental Studies Hybridoma Bank at the University of Iowa.

Complementary DNAs (cDNAs) {#s4b}
--------------------------

The full-length cDNAs of mouse *Large* (IMAGE 30725031) and mouse *Large2* (IMAGE 4980759) were purchased from Thermo Scientific Open Biosystems. To generate myc + Hisx6-tagged LARGE2 at the C-terminus, the full-length open--reading frame was amplified with a primer pair \#3793: 5′-TTGCGGCCGCTCATGCTGCCCCGAGGTCGC-3′/\#3798: 5′-CCCTCGAGGGCCCGACTTCGGGCCTGCTG-3′. The PCR product was digested with NotI and XhoI, and then subcloned into a NotI/XhoI-digested pcDNA4/myc-His-A vector (Invitrogen), designated as pcDNA4-mLarge2/myc-His.

The lentiviral constructs and establishing stable cell lines expressing LARGE or LARGE2 {#s4c}
---------------------------------------------------------------------------------------

For generating lentiviral constructs for stable expression of LARGE and LARGE2, a 3.7 kb SalI/MluI mouse *Large* cDNA fragment and a 2.4 kb MluI mouse *Large2* cDNA fragment were subcloned into the pLEX-MCS vector (Thermo Scientific Open Biosystems), respectively. The cytomegalovirus (CMV) promoter region in the vector was replaced with the hEF-1α promoter. The hEF-1α promoter region in the pEF4/Myc-His vector (Invitrogen) was amplified with a primer pair 5′-CAGGCCATGGTGGCCTCGTGAGGCTCCG-3′ and 5′-GCACTAGTACCAAGCTAATTCC-3′, and the polymerase chain reaction (PCR) product was digested with SfiI and SpeI, and then subcloned into a SfiI/SpeI-digested vector. Lentiviruses were generated by the Gene Transfer Vector Core at the University of Iowa using Trans-Lentiviral ORF Packaging System (Open Biosystems). WT or pgsI-208 CHO cells were infected with multiplicity of infection of 1 and selected in medium containing 1 μg/mL puromycin (InvivoGen). Single colonies were isolated and analyzed for expression of the LARGE or LARGE2 protein by immunoblotting.

The LARGE2dTM construct and establishing a stable cell line {#s4d}
-----------------------------------------------------------

The construct from which mouse LARGE2 is expressed without its transmembrane region was generated by amplifying the cDNA fragments of pcDNA4-Large2/myc-His. Primer pair \#7599: 5′-AAAGCGGCCGCTCGGGACCCGGATTATGGACTG---3′/\#7600: 5′-GGCCAGAGTAGTGTTTGTTGG-3′ was used to produce the left fragment, which was then digested with NotI and BamHI. The right fragment was generated by digesting pcDNA4-LARGE2/myc-His with BamHI and PmeI. The two fragments were then subcloned into a NotI/EcoRV-digested p3xFLAG-CMV-9 vector (Sigma-Aldrich) to generate construct p3xFLAG-CMV-9-LARGE2dTM. This construct encodes a LARGE2 fusion protein (amino acids 30--690) tagged with a 3xFLAG at its N-terminus and a myc-Hisx6 tag at its C-terminus. A HEK293 cell line stably expressing LARGE2dTM protein was established, and LARGE2dTM secreted into the medium was purified using a metal affinity resin as described for LARGEdTM previously ([@CWS152C17]).

Enzymatic assay {#s4e}
---------------

The HPLC-based enzymatic assay for LARGE2dTM was performed using Xyl-α-pNP or Xyl-α1,3-GlcA-β-MU as the acceptor to test for GlcA-T activity and GlcA-β-MU to test for Xyl-T activity. The methods for the assay and preparation of Xyl-α1,3-GlcA-β-MU were described previously ([@CWS152C17]). For initial characterization of the Xyl-T activity of LARGE2 (Figure [3](#CWS152F3){ref-type="fig"}A), LARGE2dTM was incubated with 2 mM GlcA-β-MU and 1 mM UDP-Xyl at 37°C for 20 min in 0.1 M MOPS buffer, pH 7.5, at 5 mM MnCl~2~, 5 mM MgCl~2~ and 0.5% Triton X-100. For the GlcA-T assay (Figure [3](#CWS152F3){ref-type="fig"}C), the reaction was carried out at 37°C overnight, with 2.5 mM Xyl-α-pNP and 5 mM UDP-GlcA in 50 mM MOPS, pH 6.0, at 10 mM MnCl~2~, 10 mM MgCl~2~ and 0.5% Triton X-100. For the assessment of donor specificity, the reaction was carried out at 37°C for 20 min, with 2 mM GlcA-β-MU in 0.1 M MOPS, pH 7.5 or 0.05 mM Xyl-α1,3-GlcA-β-MU in 0.1 M sodium acetate, pH 5.5, at 5 mM MnCl~2~, 5 mM MgCl~2~ and 0.5% Triton X-100 in the presence of 1 mM each donor sugar. The specific activities toward GlcA-β-MU and Xyl-α1,3-GlcA-β-MU were 31.7 pmol/min/μg and 5.1 pmol/min/μg, respectively, and are represented as 100% (Figure [3](#CWS152F3){ref-type="fig"}E). For the assessment of optimal pH, the following buffers were used: 0.1 M sodium acetate buffer for pH 4.0--5.5; 0.1 M 2-(*N*-morpholino)ethanesulfonic acid (MES) buffer for pH 5.5--6.5; 0.1 M 3-(*N*-morpholino)propanesulfonic acid (MOPS) buffer for pH 6.5--8.0 and 0.1 M Tris--HCl buffer for pH 8.0--9.0. The reaction was carried out at 37°C for 1 h, with 2 mM GlcA-β-MU or 0.1 mM Xyl-α1,3-GlcA-β-MU added to each of the buffers described above, at 10 mM MnCl~2~, 10 mM MgCl~2~ and 0.5% Triton X-100. The specific activity that represents 100% in each assay is: 13.7 pmol/min/μg for LARGE Xyl-T, 26.5 pmol/min/μg for LARGE GlcA-T, 20.9 pmol/min/μg for LARGE2 Xyl-T and 6.6 pmol/min/μg for LARGE2 GlcA-T. For the assessment of polymerizing activity, LARGE2dTM was incubated with 2 mM GlcA-β-MU, 5 mM UDP-Xyl and 5 mM UDP-GlcA at 37°C for 16 h, in 0.1 M MES, pH 6.5, at 10 mM MnCl~2~, 10 mM MgCl~2~ and 0.5% Triton X-100.

MS analysis {#s4f}
-----------

MS and MS/MS analyses were conducted on an Agilent 6520A Quadrupole Time of Flight (Q/TOF) mass spectrometer configured for flow-injection analysis. Borosilicate nano-capillary vials were used. The glycan samples were diluted in 50% acetonitrile and 0.1% formic acid, and loaded into the distal end of the nano vial. The capillary was fixed in a grounded stainless steel union and positioned within 8 mm of the inlet capillary to the mass spectrometer, which was maintained at −1200 V. Opposite to the inlet, the counter electrode was held at −1700 V. The Q/TOF was configured to run at high resolution (16--22 K), collecting at 4 GHz over a range from 25 to 1700 *m*/*z*.

Immunoblotting and flow cytometry {#s4g}
---------------------------------

WT or pgsI-208 CHO cells with or without overexpression of LARGE or LARGE2 were analyzed by immunoblotting of glycoproteins enriched by wheat germ agglutinin (WGA)-agarose beads and flow cytometry for cell surface staining, as described previously ([@CWS152C17]).
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